ADC Therapeutics SA (ADCT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at ADC Therapeutics SA.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 354.5% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.19 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.29 | – | 17 | 0.70 | -181.70 | -22 | -22 |
| 2025: Q1 | -0.36 | – | 23 | 27.60 | -167.60 | -56 | -57 |
| 2025: Q2 | -0.50 | – | 19 | 8.20 | -300.70 | -24 | -24 |
| 2025: Q3 | -0.30 | – | 16 | -11.00 | -249.40 | -30 | -30 |
| 2025: Q4 | -0.04 | – | 23 | 36.40 | -27.80 | -31 | -31 |
| 2026: Q1 | -0.21 | – | 21 | -9.50 | -158.10 | -30 | -30 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
ADC Therapeutics SA stellt in der Schweiz und den USA eine Antibody-Drug-Conjugate-(ADC-)Technologieplattform bereit. Das Hauptprodukt ist ZYNLONTA, ein CD19-gerichtetes ADC, das eine beschleunigte Zulassung der U. erhielt.
| Employees | 188 |
|---|---|
| Headquarters | Epalinges, Switzerland |
| Website | adctherapeutics.com |
| IPO Date | 16. Mar 1979 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Ameet Mallik M.B.A., M.S. | CEO & Director | 1973 |
| Jose I. Carmona M.B.A. | Chief Financial Officer | 1972 |
| Mohamed Zaki M.D., Ph.D. | Chief Medical Officer | 1965 |
| Lisa Michelle Kallebo | Corporate Controller & Chief Accounting Officer | – |
| David S. Ege Ph.D. | Chief Technical Officer | 1974 |
| Nicole Riley | Head of Investor Relations & Corporate Communications | – |
| Peter J. Graham Esq. | Secretary and Chief Legal & Compliance Officer | 1967 |
| Kimberly Pope | Senior VP & Chief People Officer | 1967 |
| Kristen Harrington-Smith | Chief Commercial Officer | 1973 |
| Marcy Graham | Investor Relations Officer | 1967 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.